Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

284

HTML

2582

Figures (1-2)

279

Tables (1-3)

260

Sum=3405

Mar 27, 2010 (publication date) through Feb 21, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Hepatol. Mar 27, 2010; 2(3): 103-113
Published online Mar 27, 2010. doi: 10.4254/wjh.v2.i3.103

Table 2 Summary of the results obtained so far with anti-EGFR drugs in HCC

Class	Agent	Development	Comments
Small molecules
	Erlotinib	As single-agent	Cytostatic more than cytotoxic
		In combination with bevacizumab	Active (high ORR), but toxic
	Gefitinib	As single-agent	Not active
	Lapatinib	As single-agent	Too early to draw conclusions
Monoclonal antibodies
	Cetuximab	As single-agent	Low ORR (but prolonged survival)
		In combination with chemotherapy	High DCR, but toxic

DCR: Disease control rate; ORR: Overall response rate.

Citation: Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. World J Hepatol 2010; 2(3): 103-113
URL: https://www.wjgnet.com/1948-5182/full/v2/i3/103.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i3.103